Abstract: Objective To observe the clinical efficacy of selective transcatheter chemoembolization （TACE） with biologic microsphere and lipiodol in the treatment of patients with primary liver cancer （PLC）. Methods 82 patients with PLC in Daping hospital from January 2010 to December 2012 were included in this study and were divided into two groups. 42 patients received selective transcatheter chemoembolization with lipiodol,and 40 received selective transcatheter chemoembolization with both biologic microsphere and lipiodol. Each patient got chemoembolization at least four times. The follow-up assessment was conducted 1 month later as well as 3 months,6 months,1 year and 2 years later after the first treatment to follow-up the decreased volume and number of tumor masses,serum AFP levels,the remission rates and survival. Results The remission rate of 57.44% in patients treated with both biologic microsphere and lipiodol was obviously higher than that treated with lipiodol（TACE）（5.23%,P<0.05） 3 months after the first operation. The serum level of AFP in the combined group got much lower（296.7±96.3）ng/ml than in the TACE group[（346.9±118.3）ng/ml,P<0.05] 6 months later. We found that the diameters of tumors were much smaller（3.36±1.37） cm in the combined group than in the TACE group[（4.98±1.87）cm,P<0.05] 12 months later. And the survival rate in the combined group was much higher（15.0%） than that in the TACE group[（2.3%）,P<0.05] 24 months later. Conclusions Compared with patients treated with chemoembolization and lipiodol,patients receiving chemoembolization with both biologic microsphere and lipiodol get increased remission of tumor masses,as well as decreased serum AFP levels. Selective transcatheter chemoembolization with biologic microsphere and lipiodol is effective and safe in treatment of advanced liver cancer.

Key words: Hepatoma, Biologic microsphere, Lipiodol, Selective transcatheter chemoembolization, Efficacy